HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study.

AbstractBACKGROUND:
Therapeutic paracentesis in patients with cirrhosis induces arterial vasodilatation, causes a decrease in effective arterial blood volume and leads to circulatory dysfunction, which can be prevented by intravenous albumin. However, the use of albumin, being a blood product, is controversial. Recently, terlipressin, a vasoconstrictor, has been successfully used to combat this adverse effect of therapeutic paracentesis. Therefore, the aim of the present study was to investigate the preventive effect of terlipressin on paracentesis-induced circulatory dysfunction in patients with cirrhosis after therapeutic paracentesis and compared with that of intravenous albumin.
METHODS:
Forty patients with cirrhosis and tense ascites underwent therapeutic paracentesis with albumin or terlipressin in a randomized pilot study at a tertiary center. Effective arterial blood volume was assessed by measuring plasma renin activity at baseline and at 4-6 days after treatment.
RESULTS:
Effective arterial blood volumes as indicated by plasma renin activity before and 4-6 days after paracentesis did not differ in the two groups (19.15 +/- 12.1 to 20.33 +/- 12.8 ng/mL per h, P = 0.46 in the albumin group; and 20.11 +/- 10.6 to 21.08 +/- 10.52 ng/mL per h, P = 0.44 in the terlipressin group). Plasma aldosterone concentrations before and 4-6 days after paracentesis were also similar in both groups (1334.75 +/- 1058 to 1440.0 +/- 1161 pg/mL, P = 0.06 in the albumin group; and 1473.0 +/- 1168 to 1572.29 +/- 1182 pg/mL, P = 0.24 in the terlipressin group). Both terlipressin and albumin prevented paracentesis-induced renal impairment in these patients.
CONCLUSIONS:
Terlipressin may be as effective as intravenous albumin in preventing paracentesis-induced circulatory dysfunction in patients with cirrhosis after therapeutic paracentesis.
AuthorsVirendra Singh, Ramesh Kumar, Chander Kanwal Nain, Baljinder Singh, Arun K Sharma
JournalJournal of gastroenterology and hepatology (J Gastroenterol Hepatol) Vol. 21 Issue 1 Pt 2 Pg. 303-7 (Jan 2006) ISSN: 0815-9319 [Print] Australia
PMID16460491 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Albumins
  • Plasma Substitutes
  • Vasoconstrictor Agents
  • Aldosterone
  • Lypressin
  • Terlipressin
  • Renin
Topics
  • Albumins (therapeutic use)
  • Aldosterone (blood)
  • Ascites (etiology, therapy)
  • Blood Volume
  • Female
  • Hemodynamics
  • Humans
  • Liver Cirrhosis (complications)
  • Lypressin (analogs & derivatives, therapeutic use)
  • Male
  • Middle Aged
  • Paracentesis (adverse effects)
  • Plasma Substitutes (therapeutic use)
  • Renin (blood)
  • Terlipressin
  • Vasoconstrictor Agents (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: